Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$162.00
+1.2%
$157.41
$111.09
$183.00
$9.88B0.41486,735 shs212,034 shs
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$78.69
+3.4%
$70.59
$27.30
$117.33
$8.34B0.221.13 million shs974,618 shs
Hypera S.A. stock logo
HYPMY
Hypera
$4.13
-3.2%
$3.71
$2.64
$6.02
$2.62B0.768,047 shs3,240 shs
Viatris Inc. stock logo
VTRS
Viatris
$8.29
-2.5%
$8.33
$6.85
$13.55
$9.73B0.8910.30 million shs9.91 million shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+1.23%+1.59%+0.58%+5.00%+22.05%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
+0.38%+3.72%+17.64%+19.75%+165.86%
Hypera S.A. stock logo
HYPMY
Hypera
0.00%-5.85%+22.91%+25.44%-26.21%
Viatris Inc. stock logo
VTRS
Viatris
+0.24%-3.30%+10.53%-24.44%-21.84%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.3562 of 5 stars
4.53.00.00.02.91.70.6
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
4.5059 of 5 stars
3.51.00.04.22.84.21.9
Hypera S.A. stock logo
HYPMY
Hypera
N/AN/AN/AN/AN/AN/AN/AN/A
Viatris Inc. stock logo
VTRS
Viatris
2.749 of 5 stars
2.93.02.50.01.13.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.00
Buy$216.0733.37% Upside
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
3.00
Buy$138.2575.69% Upside
Hypera S.A. stock logo
HYPMY
Hypera
0.00
N/AN/AN/A
Viatris Inc. stock logo
VTRS
Viatris
1.75
Reduce$10.5026.66% Upside

Current Analyst Ratings Breakdown

Latest HYPMY, VTRS, ASND, and CORT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/12/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.00
5/6/2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$135.00
5/6/2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$150.00 ➝ $145.00
5/5/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$180.00 ➝ $250.00
5/2/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$205.00 ➝ $210.00
5/2/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$200.00 ➝ $245.00
5/2/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$181.00 ➝ $212.00
5/2/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$260.00 ➝ $280.00
4/16/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$205.00
4/3/2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$128.00 ➝ $131.00
4/1/2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$130.00 ➝ $142.00
(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$368.70M26.79N/AN/A($1.88) per share-86.17
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$685.45M12.17$1.16 per share67.96$4.92 per share15.99
Hypera S.A. stock logo
HYPMY
Hypera
$1.59B1.65$0.69 per share6.02N/A
Viatris Inc. stock logo
VTRS
Viatris
$14.33B0.68$3.93 per share2.11$17.06 per share0.49
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$409.12M-$6.28N/A675.00N/A-104.54%N/A-39.23%N/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$106.14M$1.1662.4542.54N/A22.35%24.54%20.24%8/4/2025 (Estimated)
Hypera S.A. stock logo
HYPMY
Hypera
$330.61M$0.2417.21N/A20.04%13.18%6.19%7/23/2025 (Estimated)
Viatris Inc. stock logo
VTRS
Viatris
$54.70M-$3.17N/A3.23N/A-5.87%16.46%7.09%N/A

Latest HYPMY, VTRS, ASND, and CORT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Viatris Inc. stock logo
VTRS
Viatris
$0.49$0.50+$0.01-$2.55$3.30 billion$3.25 billion
5/5/2025Q1 2025
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$0.17$0.17N/A$0.17$177.93 million$157.21 million
5/1/2025Q1 2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$1.56-$1.66-$0.10-$1.66$98.56 million$123.97 million
4/23/2025Q1 2025
Hypera S.A. stock logo
HYPMY
Hypera
N/A-$0.04N/A-$0.04N/A$184.34 million
3/20/2025Q4 2024
Hypera S.A. stock logo
HYPMY
Hypera
N/A$0.02N/A$0.02N/A$258.56 million
2/27/2025Q4 2024
Viatris Inc. stock logo
VTRS
Viatris
$0.57$0.54-$0.03-$0.43$3.60 billion$3.53 billion
2/26/2025Q4 2024
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$0.37$0.26-$0.11$0.26$200.12 million$181.89 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/AN/AN/AN/AN/A
Hypera S.A. stock logo
HYPMY
Hypera
$0.122.91%N/A50.00%N/A
Viatris Inc. stock logo
VTRS
Viatris
$0.485.79%+13.30%N/A N/A

Latest HYPMY, VTRS, ASND, and CORT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/5/2025
Viatris Inc. stock logo
VTRS
Viatris
quarterly$0.125.55%5/23/20255/23/20256/16/2025
2/24/2025
Viatris Inc. stock logo
VTRS
Viatris
quarterly$0.125.2%3/10/20253/10/20253/18/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
1.17
0.84
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
0.01
3.70
3.64
Hypera S.A. stock logo
HYPMY
Hypera
0.68
1.81
1.41
Viatris Inc. stock logo
VTRS
Viatris
0.82
1.51
0.96

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
93.61%
Hypera S.A. stock logo
HYPMY
Hypera
N/A
Viatris Inc. stock logo
VTRS
Viatris
79.88%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
20.80%
Hypera S.A. stock logo
HYPMY
Hypera
N/A
Viatris Inc. stock logo
VTRS
Viatris
0.13%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
64060.97 million36.41 millionOptionable
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
300106.05 million83.30 millionOptionable
Hypera S.A. stock logo
HYPMY
Hypera
10,301633.42 millionN/ANot Optionable
Viatris Inc. stock logo
VTRS
Viatris
37,0001.17 billion1.19 billionOptionable

Recent News About These Companies

Peering Into Viatris's Recent Short Interest
Medicine background - stock image
2 Generic Drug Stocks Ready to Surge in 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$162.00 +1.95 (+1.22%)
Closing price 04:00 PM Eastern
Extended Trading
$161.93 -0.07 (-0.04%)
As of 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Corcept Therapeutics stock logo

Corcept Therapeutics NASDAQ:CORT

$78.69 +2.60 (+3.42%)
Closing price 04:00 PM Eastern
Extended Trading
$77.23 -1.46 (-1.86%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Hypera stock logo

Hypera OTCMKTS:HYPMY

$4.13 -0.14 (-3.17%)
As of 03:19 PM Eastern

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides sun protection and moisturizing skin care products under the Mantecorp Skincare brands; similar products under the Doralgina, Dropy D, balance, Flavonid, histamin, NeoFresh, neolefrin, Neochemistry Vitamins, Neosorum, and Torsilax brand names; and consumer health products under the Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina brands, as well as similar and generic drugs under the Neo Química brand. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and generic medicines under the Hydroxyzine, Sodium Diclofenac, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

Viatris stock logo

Viatris NASDAQ:VTRS

$8.29 -0.21 (-2.47%)
Closing price 04:00 PM Eastern
Extended Trading
$8.28 0.00 (-0.06%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.